VMD: Top line & bottom line YoY growth, Bright Outlook, 5X VMD's Q1 2022 results:
Top line YoY growth, bottom line YoY growth, operating cash flow YoY growth, free cash flow for another quarter in a row, net cash keeps going up and bright outlook:
“The record setting quarter in our core business is a reflection of the momentum we are beginning to see in a post pandemic environment,” said Casey Hoyt, CEO. “Our investments in people, technology and inventory during the pandemic have positioned us extremely well to actively engage with patients, providers, and payors as pandemic restrictions abate. We are invigorated by the increasing opportunities for face-to-face interaction with the people we serve in the coming months.”
Full article:
https://www.hmenews.com/article/viemed-healthcare-sees-investments-pay-off
With a net cash position of approximately US$24 million, US$190 million Enterprise Value and about US$35 million adj. EBITDA this year (excluding any acquisitions), VMD at US$5.50 per share trades only 5 times its adj. EBITDA.
This is the definition of a bargain. VMD is dirt-cheap both on absolute and relative valuation analysis while being a takeover target for a larger healthcare name.
Do not forget that VMD's indebted peer Apria (APR) was bought out a few weeks ago:
https://www.businesswire.com/news/home/20220329005649/en/Owens-Minor-Inc.-Completes-Acquisition-of-Apria-Inc.